New Delhi: After Thrombosis with Thrombocytopenia Syndrome (TTS), it has now been found that British-Swedish pharma giant AstraZeneca’s COVID-19 vaccine, made in collaboration with Oxford University can raise the risk of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) , a rare but fatal blood clotting disorder, claimed researchers. While not new, VITT emerged as a new disease following adenovirus vector-based Oxford-AstraZeneca vaccine sold as Covishield in India and Vaxzevria in Europe at the height of the COVID pandemic in 2021, IANS reported.
“An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4)” was found as the reason for VITT.
In separate research in 2023, scientists from Canada, North America, Germany and Italy described a virtually identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.
New Delhi: The BJP-led NDA government will introduce 15 bills, including one to amend the…
Bhubaneswar: A newborn baby, who was allegedly sold by her parents in Odisha's Balangir district,…
Mumbai: Exit polls have given Bharatiya Janata Party-led Mahayuti alliance an edge in the neck-to-neck…
Cuttack: The Orissa High Court has put the BDA's order for demolition of controversial Shree…
New York: Amid reports of deteriorating health of astronauts Sunita Williams and Butch Wilmore, it…
Mumbai: South superstar Prabhas has surpassed Bollywood King Khan Shah Rukh and ‘Dabangg’ Salman Khan…
Jajpur: Police on Thursday arrested 10 persons in connection with the alleged attack on MLA…
Bhawanipatna: Five year after the rape of a woman, Dharamgarh Additional District and Session court…